1 BTC
=
- USD
GRI Bio, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About GRI Bio, Inc. Common Stock
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Market Statistics
Trading Metrics
How to Buy GRI
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy GRI
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesGRI Bio participated in a virtual investor segment discussing its Phase 2a study interim biomarker data for Idiopathic Pulmonary Fibrosis, highlighting potential therapeutic advances in treating inflammatory and fibrotic diseases using NKT cell modulators.
Windtree Therapeutics, a biotechnology company, announced the appointment of Leanne Kelly to its board of directors. Ms. Kelly has significant public company executive experience and will serve as an independent director and chair of the audit committee.
GRI Bio, a biotechnology company, announced that the European Patent Office has issued a decision to grant a patent for its NKT cell modulator GRI-0803 and its library of over 500 proprietary compounds. The company is focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases.
GRI Bio, a biotechnology company, announced the exercise of existing warrants and the issuance of new warrants. The company intends to use the proceeds for working capital and general corporate purposes.
GRI Bio, a biotechnology company, announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024, where the CEO will provide a corporate overview and business outlook.